Praxis Precision Medicines, Inc. (PRAX) Stock Price & Analysis
Praxis Precision Medicines, Inc. (PRAX) rose 0.90% to USD 325.3 as of July 25, 2026 at 03:04 UTC, according to Nexqual real-time market data.
PRAX last closed at USD 322.4; the session ranged USD 314.62–327.51 on volume of 273,390 shares. Market capitalization is $9.07B, with a 52-week range of USD 37.19–366.52 (NMS). Source: Nexqual, July 25, 2026 at 03:04 UTC.
Key Statistics (as of July 25, 2026 at 03:04 UTC)
| Price | USD 325.3 |
|---|---|
| Change | ▲ 0.90% (up) |
| Previous Close | USD 322.4 |
| Open | USD 322.39 |
| Day Range | USD 314.62 – 327.51 |
| 52-Week Range | USD 37.19 – 366.52 |
| Volume | 273,390 shares |
| Market Cap | $9.07B |
| Exchange | NMS |
Technical Analysis (PRAX)
Nexqual's technical model rates PRAX "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 03:04 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 58.82 (neutral) |
| vs SMA50 | Above (USD 310.61) |
| MACD | 3.02 (positive) |
Analyst Ratings (PRAX)
Wall Street analysts rate PRAX "Strong Buy" based on 19 analysts, with a mean price target of USD 610.05 (range USD 162–1,201), per Nexqual as of July 25, 2026 at 03:04 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 19 |
| Mean Target | USD 610.05 |
| High Target | USD 1,201 |
| Low Target | USD 162 |
| Buy / Hold / Sell | 17 / 1 / 1 |
Earnings (PRAX)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -3.69 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -3.2 vs est -3.68 ▲ beat |
| 2025-12-31 | USD -3.5 vs est -3.13 ▼ miss |
| 2025-09-30 | USD -3.36 vs est -3.49 ▲ beat |
| 2025-06-30 | USD -3.31 vs est -3.36 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Financials & Fundamentals (PRAX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -35.32% |
| Debt / Equity | 0.1 |
| Current Ratio | 15.88 |
| Total Cash | $786.87M |
| Total Debt | $1.44M |
| Free Cash Flow | $-176.03M |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Financial Health Score (PRAX)
Nexqual rates Praxis Precision Medicines, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:04 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $787M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$282M |
| Efficiency | Critical — ROE -35%, ROA -23.0% |
Ownership (PRAX)
| Insider Ownership | +0.28% |
|---|---|
| Institutional Ownership | +117.55% |
| Shares Outstanding | 27.88M |
| Float | 24.04M |
| Short % of Float | +14.34% |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Leadership (PRAX)
Praxis Precision Medicines, Inc. is led by Marcio Silva De'Souza (age 46), President, CEO & Director, per Nexqual as of July 25, 2026 at 03:04 UTC.
| President, CEO & Director | Marcio Silva De'Souza (age 46) |
|---|---|
| CFO & Treasurer | Timothy Edwin Kelly (age 52) |
| Co-Founder and President of Research & Development | Steven Petrou B.Sc. (Hons.) |
| Chief Operating Officer | Megan T. Sniecinski (age 44) |
Major Backers & Investors (PRAX)
Notable institutional backers of Praxis Precision Medicines, Inc. include Janus Henderson Group PLC, Orbis Allan Gray Ltd, FMR, LLC, according to Nexqual as of July 25, 2026 at 03:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Janus Henderson Group PLC | 12.41% |
| Orbis Allan Gray Ltd | 8.87% |
| FMR, LLC | 7.75% |
| Perceptive Advisors Llc | 7.3% |
| Baker Bros. Advisors, LP | 6.29% |
| Deerfield Management Company, L.P | 3.46% |
| Driehaus Capital Management, LLC | 3.4% |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 3.33% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.56% |
| Vanguard Group | 9.74% |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
From Praxis Precision Medicines, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- We submitted a New Drug Application, or NDA, for ulixacaltamide for the treatment of ET to the FDA, and have commenced commercial preparations and pre-launch activities.
- We may also rely on trademarks, copyrights and trade secrets relating to our proprietary technology platform and on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of neuroscience that may be important for the development of our business.
- Solidus™ is enabled by our proprietary, computational workflow to discover ASOs with desired drug-like properties to optimize for up/down-regulation, avoidance of toxic motifs and optimization of binding affinity and specificity.
- INTELLECTUAL PROPERTY We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties.
Partnerships
- LICENSE AGREEMENTS License Agreement with RogCon In September 2019, we and RogCon, Inc., or RogCon, entered into a Cooperation and License Agreement, or the RogCon Agreement, to collaborate to develop ASOs for the treatment of epilepsy caused by mutations of the SCN2A gene.
- RogCon had an existing collaboration arrangement with Ionis Pharmaceuticals, Inc., or Ionis, and as a result, we and Ionis negotiated a Research Collaboration, Option and License Agreement, or the Ionis Agreement, (described below) in order to complete the license agreement with RogCon.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OLMA | Olema Pharmaceuticals, Inc. | USD 11.7 | ▲ 1.83% |
| KYMR | Kymera Therapeutics, Inc. | USD 110.57 | ▲ 0.21% |
| EWTX | Edgewise Therapeutics, Inc. | USD 40.84 | ▲ 6.55% |
| SRRK | Scholar Rock Holding Corporatio | USD 47.67 | ▼ 1.3% |
| STOK | Stoke Therapeutics, Inc. | USD 29.3 | ▲ 1.17% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:04 UTC. This page is informational and not investment advice.